- Home
- SSM vs BCAB Comparison
SSM vs BCAB Comparison
Compare SSM & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSM | BCAB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Germany | United States |
| Employees | 23 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SSM | BCAB |
|---|---|---|
| Price | $3.90 | $3.71 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 61.0K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $1,462,987.20 | N/A |
| Revenue Next Year | $48.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $0.12 |
| 52 Week High | $10.54 | $6.52 |
Technical Indicators
Market Signals| Indicator | SSM | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 49.53 |
| Support Level | $3.61 | $3.24 |
| Resistance Level | $4.49 | $4.22 |
| Average True Range (ATR) | 0.49 | 0.41 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 20.00 | 27.34 |
Price Performance
Historical ComparisonAbout SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and services include Complete Solar Solutions, Solar Charge Controllers, Solar Modules, Data Services, and Engineering Services. The company's single business segment manages the financing, research and development, and product commercialization.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.